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Abstract
Cancer-secreted exosomal miRNAs are emerging mediators of cancer-stromal cross-talk in the tumor environment. Our
previous miRNAs array of cervical squamous cell carcinoma (CSCC) clinical specimens identified upregulation of miR-221-
3p. Here, we show that miR-221-3p is closely correlated with peritumoral lymphangiogenesis and lymph node (LN)
metastasis in CSCC. More importantly, miR-221-3p is characteristically enriched in and transferred by CSCC-secreted
exosomes into human lymphatic endothelial cells (HLECs) to promote HLECs migration and tube formation in vitro, and
facilitate lymphangiogenesis and LN metastasis in vivo according to both gain-of-function and loss-of-function experiments.
Furthermore, we identify vasohibin-1 (VASH1) as a novel direct target of miR-221-3p through bioinformatic target
prediction and luciferase reporter assay. Re-expression and knockdown of VASH1 could respectively rescue and simulate
the effects induced by exosomal miR-221-3p. Importantly, the miR-221-3p-VASH1 axis activates the ERK/AKT pathway in
HLECs independent of VEGF-C. Finally, circulating exosomal miR-221-3p levels also have biological function in
promoting HLECs sprouting in vitro and are closely associated with tumor miR-221-3p expression, lymphatic VASH1
expression, lymphangiogenesis, and LN metastasis in CSCC patients. In conclusion, CSCC-secreted exosomal miR-221-3p
transfers into HLECs to promote lymphangiogenesis and lymphatic metastasis via downregulation of VASH1 and may
represent a novel diagnostic biomarker and therapeutic target for metastatic CSCC patients in early stages.
Introduction
Cervical squamous cell carcinoma (CSCC) is one of the
most prevalent malignancies, and its incidence in female
malignancies worldwide is ~ 15% [1]. Although the com-
bination of screening and surgery has effectively improved
the prognosis of early-stage CSCC, it is difficult to com-
pletely prevent metastasis and recurrence of CSCC, which
is the leading cause of women’s death from this disease [2].
As the major spreading route, lymphatic metastasis is an
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independent risk factor for clinical outcomes of early-stage
CSCC [3]. More than 20% of patients with early-stage
CSCC suffer from postoperative recurrence, largely owing
to the occurrence of lymphatic metastasis prior to surgery
[4, 5].
Among multiple factors underlying lymphatic metastasis,
the adaptation of the primary tumor microenvironment by
cancer to facilitate tumor cell dissemination plays an
important prometastatic role [6]. Lymphangiogenesis is the
process of growing new lymphatic vessels and correlates
with the incidence of lymphatic metastasis and poor prog-
nosis in multiple cancers [7–9]. Growing evidence revealed
that lymphatic vessels in the tumor periphery served as a
highway for tumor cells to disseminate from their primary
site to regional lymph nodes (LNs) [10, 11]. However, the
molecular mechanism of tumor-driven peritumoral lym-
phangiogenesis is not well defined.
miRNAs are small non-coding RNAs that pair to 3′-
untranslated regions (UTRs) of target mRNA, resulting in
mRNA destabilization and/or posttranscriptional suppres-
sion [12]. The biosynthesis and dysregulation of various
miRNAs is closely associated with cancer progression [13].
We have recently performed miRNA array in paired CSCC
tissues and identified upregulation of miR-221-3p [14].
Although previously considered to be only in cells,
miRNAs have also been reported to be present extra-
cellularly as a major RNA component of exosomes [15].
Exosomes are small, 30–100 nm membrane vesicles that are
secreted into the extracellular environment by multiple cell
types, including cancer cells [16]. Cancer-secreted exoso-
mal miRNAs can be transferred into recipient normal host
cells, regulating target genes, and thus regulate biological
processes in localized tumors as well as distal tissues [17,
18]. Exosomal miRNAs reflect the expression patterns of
dysregulated miRNAs in cancer cells to a certain extent
[19]. Therefore, cancer-secreted exosomal miRNAs are
important regulatory molecules in mediating cancer–host
cross-talk.
In this study, miR-221-3p was closely correlated with
peritumoral lymphangiogenesis and LN metastasis. More-
over, it was also highly enriched in exosomes secreted from
CSCC cell lines compared with non-carcinoma epithelial
cell line. Although our previous study has reported that
miR-221-3p enhanced the malignancy of CSCC cells [14],
its roles in lymphangiogenesis and lymphatic metastasis of
CSCC need to be further investigated.
To address this problem, we performed the current study
to investigate the underlying molecular mechanisms for
cancer-secreted exosomal miR-221-3p in regulating lym-
phangiogenesis and lymphatic metastasis in CSCC, as well
Fig. 1 Upregulation of miR-221-3p in the primary tumor positively
correlates with lymph node metastasis of CSCC. a ISH scores
(HSCORE) of miR-221-3p were analyzed between the LN-N (LN
negative; n= 64) and LN-P (LN positive; n= 43) groups in CSCC
specimens. b Staining of miR-221-3p and LYVE1 (lymphatic marker)
in serial sections of CSCC specimens. Representative micrographs are
shown (left). The tumor cells are indicated by black arrows. The
lymphatic vessels are indicated by red arrows. Correlations between
miR-221-3p staining and peritumoral lymphatic vessel density
(PLVD) were analyzed (right). Scale bar, 50 µm. Error bars represent
the mean ± SD of three independent experiments. ***, P < 0.001
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as its clinical relevance, to explore the potential clinical
applications in diagnosis and therapy.
Results
Upregulation of miR-221-3p positively correlates
with LN metastasis of CSCC
To identify the correlation between miR-221-3p levels and
LN metastasis of CSCC, miR-221-3p levels were examined
in 107 paraffin-embedded human CSCC serial sections
using in situ hybridization (ISH). Compared with the LN-
negative group, a significantly high level of miR-221-3p
was detected at the primary tumor site in the LN-positive
group (Fig. 1a). Correspondingly, higher miR-221-3p levels
strongly correlated with the increment of peritumoral lym-
phatic vessel density (PLVD) in serial sections of CSCC
specimens, as indicated by LYVE1-positive vessels using
immunohistochemistry (IHC) (r= 0.498, P < 0.001) (Fig.
1b). More importantly, as shown in Fig. 1b, in addition to
tumor cells, high miR-221-3p levels were also present in
some peritumoral lymphatic vessels. Taken together, these
results suggested that high levels of miR-221-3p expression
may promote lymphangiogenesis and facilitate lymphatic
metastasis in CSCC.
miR-221-3p can be enriched in CSCC-secreted
exosomes and transferred to LECs
Previous studies have suggested that miRNAs could be
transferred intercellularly by exosomes [20]. Therefore, we
investigated whether exosomes were also involved in miR-
221-3p delivery from CSCC cells to human lymphatic
endothelial cells (HLECs). Exosomes were initially purified
from the supernatant of Siha and Ect1 cells. Typical cup-
shaped morphology and a size range of 30–100 nm was
confirmed by transmission electron microscopy (Fig. 2a).
The exosomal positive markers including CD63 and CD81
were detected by western blot (Fig. 2b). Purified exosomes
were then labeled with a fluorescent membrane tracer
PKH67 (green) and incubated with human lymphatic
endothelial cells (HLECs) and mouse lymphatic endothelial
cells (MLECs). After 48 h incubation, exosome fused cells
were stained by phalloidin (red) and 4′,6-diamidino-2-
phenylindole (blue) for confocal microscopy evaluation. A
green fluorescent punctuating signal inside the cytoplasm of
recipient HLECs indicated the internalization of exosomes
(Fig. 2c). The same phenomenon was also observed in
MLECs incubated with PKH67-labeled exosomes (Fig.
S1A).
Furthermore, we found that miR-221-3p was enriched in
CSCC-secreted exosomes, especially from C33a and Siha
(Fig. 2d), relative to their cellular content and compared
with exosomes secreted by non-carcinoma epithelial (Ect1).
To confirm that CSCC-secreted miR-221-3p can be trans-
ferred to HLECs and MLECs via exosomes, we measured
the miR-221-3p levels in HLECs and MLECs pre-treated
with CSCC-secreted exosomes. An increase of the cellular
levels of miR-221-3p was observed in recipient HLECs and
MLECs following treatment with CSCC-secreted exosomes
(Fig. 2e and Fig. S1B). Taken together, these results suggest
that horizontal transfer of miRNA-221-3p from CSCC cells
to LECs can be performed cross-species via exosomes.
CSCC-secreted exosomal miR-221-3p promotes
lymphangiogenesis in vitro
To investigate the role of exosomal miR-221-3p in lym-
phangiogenesis, lentiviral vector overexpressing miR-221-
3p or negative control (NC) was transfected into Ect1 (low
miR-221-3p), and the lentiviral vector silencing miR-221-
3p or NC was applied to Siha (high miR-221-3p). Quanti-
tative reverse transcriptase-polymerase chain reaction (qRT-
PCR) analysis showed that cellular and exosomal miR-221-
3p levels were significantly higher in of Ect1/miR-221-3p
and Siha/anti-NC compared with Ect1/miR-NC and Siha/
anti-221-3p (Fig. 3a, b). Then, HLECs and MLECs incu-
bated with exosomes secreted by Ect1/miR-NC (low miR-
221-3p), Ect1/miR-221-3p (high miR-221-3p), Siha/anti-
NC (high miR-221-3p), and Siha/anti-221-3p (low miR-
221-3p) for 48 h were analyzed for proliferation, migration,
and tube formation assays. The results showed that exo-
somes with high miR-221-3p dramatically promoted
HLECs and MLECs migration and tube formation com-
pared with those with low miR-221-3p (Fig. 3c–e and Fig.
S2C–E). Interestingly, proliferation of HLECs and MLECs
seemed to not be affected by exosomes with high or low
miR-221-3p (Fig. S2A–B). Collectively, these results sug-
gest that exosomal miR-221-3p promotes lymphangiogen-
esis in vitro.
CSCC-secreted exosomal miR-221-3p promotes
lymphangiogenesis and lymphatic metastasis
in vivo
The effect of exosomal miR-221-3p on CSCC lym-
phangiogenesis and lymphatic metastasis was assessed
in vivo using a popliteal LN metastasis model. We first
randomly established footpad xenografts using mCherry-
labeled Siha/anti-221-3p or Siha/anti-NC cells (n= 3/group,
repeated twice). Tumor sizes in Siha/anti-221-3p group
were much smaller and expressed lower levels of miR-221-
3p comparing with the Siha/anti-NC group (Fig. S3A–B).
To exclude the effect of different tumor size on LN
metastasis [21], popliteal LNs were harvested and analyzed
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IHC for mCherry expression when the primary tumors
reached ~ 150 mm3. We found that Siha/anti-221-3p group
had non-metastatic popliteal LNs compared with Siha/anti-
NC group (Fig. S3C).
According to the above data, we further inoculated
mCherry-labeled Siha/anti-221-3p cells into the footpads of
nude mice. At the time point when the tumor size reached
50 mm3, exosomes secreted by Ect1/miR-NC, Ect1/miR-
221-3p, Siha/anti-NC, or Siha/anti-221-3p were then ran-
domly injected into the center of the xenograft tumors (n=
3/group, repeated twice) twice a week. When the primary
tumors grew to ~ 150 mm3 after five injections, we killed
the mice and harvested the tumors and the associated
popliteal LNs for ISH and IHC analysis. A significantly
higher level of miR-221-3p was both present in some
peritumoral lymphatic vessels and tumor cells treated exo-
somes with high miR-221-3p secreted from Ect1/miR-221-
3p and Siha/anti-NC compared with those with low miR-
221-3p secreted from Ect1/miR-NC and Siha/anti-221-3p
(Fig. 4a). Meanwhile, we performed qRT-PCR analysis for
miR-221-3p expression and conformed ISH results (Fig.
S4A–B). Furthermore, there was a strong positive correla-
tion between miR-221-3p expression and PLVD (Fig. 4a).
In addition, a higher ratio of metastasis-positive popliteal
LNs was found in groups with high exosomal miR-221-3p
compared with those with low exosomal miR-221-3p (Fig.
4b, c). Interestingly, although tumor size was larger in
exosomes with high miR-221-3p groups (Fig. S5A), there
were no significant differences in micro-vessel density for
the comparable tumor sizes after treatment with exosomes
with high or low miR-221-3p groups (Fig. S5B). Taken
together, these results indicate that CSCC-secreted exoso-
mal miR-221-3p could promote lymphangiogenesis and LN
metastasis in vivo.
CSCC-secreted exosomal miR-221-3p targets
lymphatic VASH1 to induce lymphangiogenesis
Multiple algorithms (miRWalk, PicTar, and TargetScan)
were used to identify the candidate targets of miR-221-3p.
As a result, 135 target genes were predicted to be regulated
by miR-221-3p (Table S4). Among these candidates,
vasohibin-1 (VASH1) functioned as a negative regulator of
lymphangiogenesis confirmed by Gene Ontology Con-
sortium (Table S5) and was chosen for further study [22].
To examine miR-221-3p regulation of the putative target
VASH1, the predicted miR-221-3p-binding site in the 3′-
UTR of VASH1 (wild type) or the mutated sequence
Fig. 2 miR-221-3p can be enriched in CSCC-secreted exosomes and
transferred to HLECs. a Morphology of Ect1 and Siha-secreted exo-
somes was confirmed by transmission electron microscopy. Scale bar,
50 nm. b Positive markers (CD63 and CD81) of Ect1 and Siha-
secreted exosomes were detected by western blot. c Human lymphatic
endothelial cells (HLECs) pre-treated with PKH67-labeled exosomes
secreted by Ect1 and Siha for 48 h were stained by phalloidin (red) and
DAPI (blue) for confocal microscopy analysis. Scale bar, 20 µm. d
Basic miR-221-3p levels in indicated cells and paired exosomes were
detected by qRT-PCR. e miR-221-3p levels in HLECs pre-treated with
PBS or indicated exosomes for 24 h were detected by qRT-PCR. Exo,
exosomes. miR-221, miR-221-3p. Error bars represent the mean ± SD
of three independent experiments
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(mutant type) were cloned into luciferase reporter plasmids
and assessed for their response to miR-221-3p in HLECs.
The results showed that the expression of the reporter gene
followed by a wild type 3′-UTR of VASH1 was sig-
nificantly reduced by the co-transfected miR-221-3p mimic,
whereas reporter gene expression had no change if followed
by the 3′-UTR of the VASH1 gene with a mutated putative
target site of miR-221-3p (Fig. 5a). Thus, we concluded that
VASH1 is a direct target of miR-221-3p.
Consistent with the results from the luciferase reporter
assay, treatment with miR-221-3p mimic or exosomes
derived from Ect1/miR-221-3p and Siha/anti-NC but not
the Ect1/miR-NC and Siha/anti-221-3p resulted in a sig-
nificant decrease of VASH1 expression in HLECs for both
RNA and protein levels (Fig. 5b, c). Re-expression VASH1
rescued, whereas silencing VASH1-simulated down-
regulation of VASH1 mediated by exosomes with high
levels of miR-221-3p (Fig. 5d, e).
Further in vitro studies confirmed that re-expression of
VASH1 could abrogate Ect1/miR-221-3p and Siha/anti-NC
exosomes-mediated promotion of migration and tube for-
mation of HLECs, whereas silencing VASH1 could pro-
voke Ect1/miR-NC and Siha/anti-221-3p exosomes'
abilities to induce migration and tube formation in HLECs
(Fig. 5f, g and Fig. S6A–B). Collectively, these results
indicated that exosomal miR-221-3p induced lymphangio-
genesis via suppressing VASH1 expression in HLECs.
Growing evidence has suggested that the ERK and AKT
pathways are involved in lymphangiogenesis and lymphatic
metastasis [23], which prompted us to determine whether
the ERK and AKT pathways could be activated by exoso-
mal miR-221-3p. We found that phosphorylation of ERK1/
2 and AKT was significantly increased in exosomes with
high miR-221-3p groups rather than those with low miR-
221-3p groups (Fig. S7A). In addition, as a classic lym-
phangiogenic growth factor, tumor-derived VEGF-C could
also induce lymphangiogenesis via activation of the ERK
and AKT signaling pathways in HLECs [24], and the
relationship between miR-221-3p and VEGF-C expression
was further examined in CSCC. Interestingly, qRT-PCR
Fig. 3 CSCC-secreted exosomal miR-221-3p promotes lymphangio-
genesis in vitro. a Cellular and exosomal miR-221-3p levels in
Ect1 stably transfected with miR-221-3p overexpression (miR-221) or
negative control (miR-NC) lentivectors were detected by qRT-PCR. b
Cellular and exosomal miR-221-3p levels in Siha stably transfected
with miR-221-3p knockdown (anti-221) or negative control (anti-NC)
lentivectors were detected by qRT-PCR. c Transwell migration assay
in HLECs pre-treated with indicated exosomes. Average migrated cells
per field were calculated. d Tube formation assay in HLECs pre-
treated with indicated exosomes. Average length of tubes per field
were calculated. e Representative micrographs of migration (upper
panel) and tube formation assay (lower panel) in HLECs pre-treated
with indicated exosomes are shown. Scale bar, upper panel, 50 µm;
lower panel, 100 µm. miR-NC exo, Ect1/miR-NC secreted exosomes.
miR-221 exo, Ect1/miR-221-3p secreted exosomes. anti-NC exo, Siha/
anti-NC secreted exosomes. anti-221 exo, Siha/anti-221-3p secreted
exosomes. Error bars represent the mean ± SD of three independent
experiments. **, P < 0.01; ***, P < 0.001
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and ELISA showed that miR-221-3p overexpression in Ect1
or miR-221-3p knockdown in Siha did not induce VEGF-C
mRNA or protein changes (Fig. S7B). Therefore, we con-
cluded that the miR-221-3p-VASH1 axis activated AKT
and ERK signaling pathways might work in a VEGF-C
independent manner in HLECs.
CSCC-secreted exosomal miR-221-3p is associated
with VASH1 expression and lymphatic metastasis
To investigate whether cancer-secreted miR-221-3p can be
detected in the circulation (peripheral blood) of CSCC
patients, exosomes were isolated and characterized in the
circulation of stage I–II CSCC patients with (n= 20) or
without LN metastasis (n= 20). Typical morphology, size
range, and associated proteins found in purified exosomes
from the circulation were consistent with those from con-
ditioned media (Fig. S8A–B). Moreover, circulating exoso-
mal miR-221-3p expression was significantly higher in the
circulation when isolated from LN-positive patients than
from LN-negative patients (Fig. 6a). To further investigate
whether circulating exosomal miR-221-3p in CSCC patients
is functionally active in regulation of HLECs, we treated
HLECs with circulating exosomes from LN-negative
patients with low level miR-221-3p or LN-positive patients
with high level miR-221-3p to perform a HLECs sprout
assay. The results showed that circulating exosomes from
LN-positive patients, but not LN-negative patients, increased
sprouting lymphangiogenesis of HLECs, which could be
abolished by yc=12?> miR-221-3p inhibitors (Fig. 6b).
In patients with paired circulation and tumor specimens,
we found that circulating exosomal miR-221-3p level was
Fig. 4 CSCC-secreted exosomal miR-221-3p promotes lymphangio-
genesis and lymphatic metastasis in vivo. a popliteal lymph node
metastasis model was established in nude mice by inoculating the
footpad with Siha/anti-221-3p (5 × 106) stably expressing mCherry.
When footpad tumor size reached 50 mm3, exosomes (10 µg) secreted
by Ect1/miR-NC, Ect1/miR-221-3p, Siha/anti-NC, or Siha/anti-221-3p
were then injected into the center of the tumors (n= 3/group, repeated
twice) twice a week. After five injections, primary tumors reached a
comparable size of ~ 150 mm3, and then footpad tumors and popliteal
LNs were collected for study. a Staining of miR-221-3p and LYVE1
in serial sections of mice footpad tumors. Representative micrographs
of positive staining are shown (left). The tumor cells are indicated by
black arrows. The lymphatic vessels are indicated by red arrows. The
correlation between miR-221-3p levels and PLVD was statistically
analyzed (right). Scale bar, 20 µm. b Staining of mCherry in popliteal
LNs from mice treated with the indicated exosomes. Representative
micrographs are shown. Metastasis-positive LNs were identified by
staining for cancer cell-expressed mCherry. Scale bar, upper panel,
200 µm; lower panel, 20 µm. c The ratio of metastasis-positive to total
dissected popliteal LNs from mice treated with the indicated exo-
somes. ***, P < 0.001
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positively associated with tumor miR-221-3p levels (r=
0.721, P < 0.001) and lymphangiogenesis (r= 0.512, P <
0.001) but was negatively correlated with VASH1 expres-
sion (r=− 0.588, P < 0.001) (Fig. 6c). Immuno-
fluorescence and ISH in human CSCC tissues also
demonstrated that high miR-221-3p levels in tumor were
accompanied by reduced VASH1 expression in LYVE1-
positive lymphatic vessels and enhanced PLVD. These
observations further supported our conclusion that the
CSCC-secreted exosomal miR-221-3p promoted lym-
phangiogenesis via downregulating VASH1 expression in
HLECs and then facilitated lymphatic metastasis (Fig. 6d).
Discussion
Tumor-induced peritumoral lymphangiogenesis has been
reported to enhance the lymphatic dissemination of tumor
cells to regional LNs [25]. The occurrence of regional LN
metastasis at an early stage is considered to be a crucial step
in CSCC progression [26]. Therefore, it is necessary to
identify novel and effective biomarkers that discriminate
between indolent and aggressive CSCC that can contribute
to developing personalized diagnostic and therapeutic stra-
tegies for patients with different progression risks. Recently,
circulating exosomal miRNAs have been recognized to be
promising biomarkers for cancer patients owing to their
profile of expression potentially reflecting dysregulated
expression patterns in multiple human cancer types, as well
as their non-invasive diagnostic approach and high stability
in circulation [27, 28]. Here, our clinical evidence revealed
that circulating exosomal miR-221-3p promoted lym-
phangiogenesis in vitro and was associated with PLVD and
LN metastasis in patients with CSCC, suggesting that cir-
culating exosomal miR-221-3p may serve as a diagnostic
biomarker and therapeutic target for metastatic CSCC.
Fig. 5 CSCC-secreted exosomal miR-221-3p targets lymphatic
VASH1 to induce lymphangiogenesis in HLECs. a RNA sequence
alignment between miR-221-3p and the 3′-UTR of VASH1 (left), and
the effect of miR-NC and miR-221-3p on the activity of the luciferase
reporter containing either wild type (WT) or mutant type (MT) were
tested by dual-luciferase reporter assay (right). b–c RNA and protein
levels of VASH1 were, respectively, detected by qRT-PCR and wes-
tern blot in HLECs transfected with miR-221-3p mimic or negative
control (NC) compared with those treated with the indicated exo-
somes. d–e RNA and protein levels of VASH1 were, respectively,
detected by qRT-PCR and western blot in HLECs treated with indi-
cated exosomes in the presence of VASH1 overexpression plasmid
(VASH1) or vector control and VASH1 silence fragment (siVASH1)
or siRNA control. f–g Overexpression of VASH1 rescued the biologic
effects associated with exosomal miR-221-3p, whereas knockdown of
VASH1 simulated the biologic effects associated with exosomal miR-
221-3p through cell migration and tube formation assays. Error bars
represent the mean ± SD of three independent experiments. *, P <
0.05; **, P < 0.01; ***, P < 0.001
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Many studies devoted to miRNAs expression profiling
have shown significantly altered miRNAs signatures in
various stages of cancer metastasis [29]. Our previous study
also confirmed that higher miR-221-3p could be found in
metastatic CSCC patients and it enhanced the malignancy
of CSCC cells [14]. However, the metastasis cascade is not
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only dependent on miRNAs alternations within a subset of
cancer cells but also involves interactions with surrounding
cells that may significantly contribute to cancer progression
[30]. Recently, cancer-secreted exosomal miRNAs have
emerged as highly versatile regulators in this communica-
tion process [31]. Zhou et al.[32] reported that uptake of
cancer-secreted miR-105 by vascular endothelial cells pro-
voked vascular permeability and metastatic dissemination.
In this study, we found that CSCC-secreted miR-221-3p
could be horizontally transferred to LECs to promote lym-
phangiogenesis, thus facilitating lymphatic metastasis.
Interestingly, cancer-secreted exosomes were able to
directly transfer into LECs and other cells in LN (Fig. S9).
The role of exosomal miRNAs in the tumor draining LNs is
currently under investigation in our laboratory. Cancer-
secreted miRNAs have also been reported to promote
angiogenesis to accelerate tumor growth and metastasis
[33]. Our study also found that miR-221-3p levels posi-
tively correlated with the MVD (Fig. S10). To exclude this
confounding factor, we set up experiments to collect tumors
at similar sizes after the indicated treatment to analyze the
relationship among PLVD, microvascular density (MVD),
and LN metastasis. Higher PLVD rather than MVD was
positively correlated with LN metastasis (Fig. 4 and Fig.
S5), implying that lymphangiogenesis may be more
important than angiogenesis in CSCC LN metastasis. It is
also intriguing why exosomal miR-221-3p does not affect
LECs proliferation. A recent study by Kuehbacher et al.
[34] found that non-specific silencing of miRNAs sup-
pressed angiogenic activity, indicating the complexity of
miRNAs-dependent regulation of angiogenesis. Similar to
angiogenesis, lymphangiogenesis is also influenced by
miRNAs [35]. We, therefore, concluded that CSCC-
secreted miR-221-3p have an important role in a part of
lymphangiogenesis as a result of increased migration and
tube formation.
Various genes and pathways have been identified to be
direct targets of miR-221-3p. For example, miR-221-3p
targeted the JAK/STAT signaling pathway by directly
inhibiting the expression of SOCS3 and IRF2 [36]. Here,
we showed that VASH1, which was previously shown to
negatively regulate lymphangiogenesis in our large pre-
dicted target cohorts, is of great interest as a downstream
target of miR-221-3p, and our data confirmed that VASH1
was a novel direct target of miR-221-3p by luciferase
reporter assay. Recognized as an endogenous angiogenesis
inhibitor induced by vascular endothelial growth factor
(VEGF) and fibroblast growth factor 2, VASH1 was proven
to downregulate angiogenesis through a negative feedback
mechanism under physiological conditions [37]. Never-
theless, this negative feedback system may be defective in
tumor angiogenesis, as factors in the tumor microenviron-
ment such as hypoxia and inflammation inhibit VASH1
expression in endothelial cells [38]. Considerable research
suggested that knockdown of VASH1 might be a crucial
driver of tumor lymphangiogenesis [22, 39]. Our results are
consistent with these reports, namely, that re-expression and
knockdown of VASH1 could, respectively, rescue and sti-
mulate the effects of lymphangiogenesis induced by exo-
somal miR-221-3p in vitro. VASH1 was previously
reported to be expressed in vascular endothelial cells but not
in lymphatic endothelial cells in human lung cancer tissue
[40], our data also revealed that reduced expression of
lymphatic VASH1 accompanied by increased PLVD in
CSCC specimens. There may be tissue-specific and cancer
type-specific mechanisms for VASH1 expression in lym-
phatic cells. In this paper, we propose a new mechanism
whereby CSCC-secreted miR-221-3p may promote lym-
phangiogenesis via downregulating VASH1.
It is noteworthy that exosomal miR-221-3p engage in
transferring genetic information, whereas lymphangiogenic
growth cytokines such as VEGF-C represents are small pro-
tein cytokines, and there are therefore two different interacting
methods involved in manners for signal transmission between
cancer cells and HLECs. Previous studies have demonstrated
that VEGF-C signaling induced lymphangiogenesis via acti-
vation of the ERK and AKT pathways [24]. In our study, we
found that HLECs treated with exosomes with high miR-221-
3p led to an increase of phosphorylation of AKT and ERK1/2
proteins (Fig. S7A), which presents a potential mechanism for
intercellular miR-221-3p-VASH1 axis induced lymphangio-
genesis in CSCC. These results implied that the miR-221-3p-
VASH1 axis and VEGF-C might share the same downstream
pathways for lymphangiogenesis. Although miR-221-3p was
reported to increase VEGF transcription in bladder cancer
cells [41], our results found that miR-221-3p overexpression
and knockdown did not induce VEGF-C mRNA or protein
Fig. 6 CSCC-secreted exosomal miR-221-3p is associated with
VASH1 expression and lymphatic metastasis. a miR-221-3p levels in
circulating exosomes of CSCC patients with LN-N (LNs negative; n
= 20) and LN-P (LNs positive; n= 20) were detected by qRT-PCR. b
Sprout assay in HLECs pre-treated with circulating exosomes from
LN-N patients with low miR-221-3p levels or LN-P patients with high
miR-221-3p levels in the presence of miR-221-3p inhibitor (anti-221)
or negative control (NC). Representative micrographs are shown (left).
Average sprouts per spheroid were calculated (right). Scale bar, 50 µm.
c Correlation analyses of exosomal miR-221-3p, tumor miR-221-3p,
peritumoral lymphatic vessel density and VASH1 levels in the above
CSCC patients. CSCC specimens subjected to ISH for tumor miR-
221-3p and double-label IF for stromal VASH1 (red) and LVYE1
(green). Representative staining micrographs are shown (upper panel).
T, tumor. Scale bar, 20 µm. Paired circulating exosomal miR-221-3p
levels in CSCC patients were detected by qRT-PCR. Correlation
analyses were calculated between two sets of quantified data as indi-
cated (lower panel). d Illustrative model showing the mechanism
whereby CSCC-secreted exosomal miR-221-3p promotes lym-
phangiogenesis by downregulating lymphatic VASH1 expression that
then facilitates lymphatic metastasis. Error bars represent the mean ±
SD of three independent experiments. * P < 0.05; ***, P < 0.001
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changes in CSCC cells (Fig. S7B). Considering the variations
among different types of tumors, there may be tissue-specific
mechanisms of VEGF-C regulation in response to miR-221-
3p. Therefore, we considered that the miR-221-3p-VASH1
axis activated AKT and ERK signaling pathways and might
work in a VEGF-C independent manner in HLECs. Devel-
oping personalized therapeutics, such as VEGF-C indepen-
dent lymphangio-miR-221-3p that might serve as
antilymphangiogenic targets in combination with current anti-
VEGF-C therapies, seems a promising direction in the treat-
ment of early-stage CSCC patients with LN metastasis.
In conclusion, our data provided evidence that high levels
of circulating exosomal miR-221-3p are associated in CSCC
with LN metastasis and are positively correlated with PLVD.
Horizontal transfer of CSCC-secreted exosomal miR-221-3p
into HLECs may promote lymphangiogenesis by regulating
VASH1 signaling, which then promotes lymphatic metas-
tasis. The newly identified intercellular miR-221-3p-VASH1
axis illustrated a critical molecular mechanism of CSCC
progression and provided a novel diagnostic and therapeutic
target for CSCC patients with LN metastasis.
Materials and methods
Cell lines
Human cervical squamous carcinoma cell lines Siha, Caski,
C33a, MS751, ME180, and a non-carcinoma cervical epi-
thelial HPV-16 E6/E7 transformed cell line, Ect1/E6E7
(Ect1), were all purchased from the ATCC and cultured
according to their guidelines. HLECs and MLECs were
respectively purchased from ScienCell and Cell Biologics
and cultured in endothelial cell medium (ScienCell) with
5% fetal bovine serum (FBS; Gibco).
Clinical specimens
CSCC specimens were obtained from voluntarily consent-
ing patients without preoperative radiotherapy or che-
motherapy at the Department of Gynecological Oncology of
Nanfang Hospital (Guangzhou, PR China) between 2012
and 2014. The study was approved by the Institutional
Research Ethics Committee. Detailed information on clin-
ical specimens and research purposes are summarized in
Supplementary Table S1–S2.
Exosomes isolation and identification
A total of 10 ml cell conditioned medium or 250 µl serum
was mixed with ExoQuick exosome precipitation solution
and exosomes isolation was conducted according to the
manufacturer’s protocol. After incubation overnight, the
ExoQucik/biofluid mixture was centrifuged at 1500 × g for
30 min at 4 °C. The pelleted exosomes were subjected to
electron microscope, protein assay, RNA extraction, in vitro
treatment, or in vivo administration. For transmission
electron microscopy (TEM), exosomes were fixed with 2%
glutaraldehyde, loaded onto carbon-coated grids, and then
negative-contrast stained with phosphotungstic acid. The
grids were visualized by TEM (Hitachi). For protein assay,
the exosome preparations used BCA Protein Assay Kit
(Beyotime). For RNA extraction from exosomes, we used
miRNeasy Mini Kit (Qiagen). For in vitro treatment, 10 µg
of exosomes resuspended in 100 µl phosphate-buffered
saline (PBS) were added to 1 × 105 recipient cells for 48 h.
For in vivo administration, 10 µg of exosomes resuspended
in 20 µl PBS were injected into the center of the xenograft
tumors twice a week. Purified exosomes were labeled with
PKH67 (Sigma) as described previously [42].
RNA extraction and qRT-PCR
RNA was extracted from cell lines, human CSCC tissues
and tumor xenografts by TRIzol (Invitrogen). qRT-PCR
was performed as previously described [43]. Specific primer
sets for miR-221-3p and U6 were purchased from RiboBio
Inc. The expression of miRNAs and mRNAs was normal-
ized to U6 and GAPDH, respectively. The primer sequences
are shown in supplementary Table S3.
Immunohistochemistry
Tissue sections were subjected to IHC analysis as described
previously [44]. The primary antibodies were as follows:
anti-VASH1 (ab176114, Abcam), anti-CD31 (ab28364,
Abcam), anti-LYVE1 (ab33682, Abcam), and anti-mCherry
antibody (ab167453, Abcam). The secondary antibodies
were horseradish peroxidase-conjugated anti-rabbit
immunoglobulin-G antibody (ab6721, Abcam). Peritumoral
lymphatic vessel density and micro-vessel density in tumor
tissues were respectively determined by the number of
LYVE1-positive vessels and CD31-positive vessels
according to the methods described by Gombos [45].
In situ hybridization
ISH was performed as described by Que [46].
Staining assessment
The immunohistochemically and in situ hybridized stained
tissue sections were reviewed and scored separately by two
independent pathologists. For semi-quantitative evaluation
of LYVE1 and miR-221-3p expression in tissue sections, a
scoring system HSCORE was used as previously described
C.-F. Zhou et al.
[47]. HSCORE ≤ 2 was classified as low expression, and
HSCORE > 2 was classified as high expression.
Western blot
Western blot assay was performed as previously described
[48]. The primary antibodies were as follows: anti-CD63
(ab68418, Abcam), anti-CD81(ab109201, Abcam), and
anti-VASH1 (ab176114, Abcam); anti-phospho-AKT
(9271, CST), anti-AKT (9272, CST), anti-phospho-ERK1/
2 (4370, CST), anti-ERK1/2 (4695, CST), and anti-GAPDH
antibody (2118, CST). The secondary antibodies were
horseradish peroxidase-conjugated anti-rabbit
immunoglobulin-G antibody (ab6721, Abcam).
Immunofluorescence
Serial paraffin sections (4 µm) from human CSCC tissues
were analyzed by immunofluorescence with the Opal 4-
Color Kit (PerkinElmer) according to the manufacturer’s
protocol. After deparaffinization, sections were microwaved
in antigen retrieval buffer for 45 s at 100 °C, washed and
blocked for 10 min at room temperature, followed by
incubation with anti-VASH1 antibody (ab176114, Abcam).
Horseradish peroxidase-conjugated secondary antibody was
dropped onto slides for incubation for 10 min at room
temperature. Subsequently, tyramide signal amplification
(TSA) working buffer (Opal 570) was used to amplify the
signal on slides. After eliminating anti-VASH1 and sec-
ondary antibodies by microwaving, the above procedures
were repeated with anti-LYVE1 antibody (ab33682,
Abcam) and TSA working buffer (Opal 520). Sections were
mounted in neutral gum and visualized by a fluorescence
microscope (Olympus). The fluorescence intensity of
VASH1 expression was analyzed by ImageJ software.
Stable transfection with lentiviral vector
Lenti-mecherry containing an miR-221-3p overexpression
sequence and its negative control RNA (miR-NC), or con-
taining an miR-221-3p knockdown segment and its negative
control vector (anti-NC) were all purchased from Gene-
Chem Inc. Ect1 and Siha cells were transfected with lenti-
mCherry/miR-221-3p and stably expressing mCherry
fluorescent protein signals were selected for further
experiments by flow cytometer.
Transient transfection with oligonucleotides and
plasmids
The miR-221-3p mimic and its NC were designed and
cloned by RiboBio Inc. The VASH1-coding sequence
(without 3′-UTR) was cloned into pCDNA3.1(+ )-Vector
(Invitrogen). The empty vector was used as a blank control.
siVASH1 and its NC siRNA were designed and synthesized
by GenePharma Inc. Lipofectamine 2000 Reagent (Invi-
trogen) was then used to transfect miR-221-3p mimic,
siVASH1, and pCDNA3.1(+ )-VASH1 according to the
manufacturer’s protocol. For RNA extraction, western blot
and in vitro functional assays, cells were used 48 h after
transfection. The sequence of siVASH1 and siRNA are
shown in supplementary Table S3.
Luciferase reporter assay
The expression of miR-221-3p targeted gene was measured
by using a dual-luciferase reporter assay in 293 T cells. The
putative miR-221-3p complementary site in the 3′-UTR of
VASH1 or its mutant sequence was cloned into the pmiR-
RB-REPORT vector (RiboBio Inc.). Then, pmiR-RB-
REPORT-VASH1-3′-UTR-WT or pmiR-RB-REPORT-
VASH1-3′-UTR-MT were co-transfected into 293 T cells
with miR-221-3p mimic or its NC in 48-well plates, col-
lected 48 h after transfection and analyzed by using a Dual-
Luciferase Reporter Assay System (Promega). Firefly luci-
ferase signal was used for normalization.
Bioinformatic miRNAs target prediction
Three online programs TargetScan, miRWalk, and PicTar
were used to predict potential target genes for miR-221-3p.
The Gene Ontology Consortium was used to identify
negative regulators of lymphangiogenesis.
HLECs tube formation assay
HLECs tube formation assay was performed as described in
our previous study [44].
HLECs sprouting assay
HLECs were coated on microcarrier-beads (Sigma) in a
ratio of 106 cells per 2000 beads and incubated for 4 h at 37
°C. After culture in a six-well dish for 24 h, coated beads
were embedded in a solution of fibrinogen in EGM2 med-
ium, and then overlaid with normal human lung fibroblasts
in a 24-well dish. Images were captured under a phase
contrast microscope (Olympus).
Transwell migration assay
In total, 1 × 105 cells in 200 µl 1640 medium without FBS
were seeded on a fibronectin-coated polycarbonate mem-
brane insert in a Transwell apparatus (Corning). In the
lower chamber, 600 µl 1640 with 10% FBS was added as a
chemoattractant. After the cells that invaded to the bottom
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of the insert membrane were fixed with methanol, the insert
was stained with Giemsa (Sigma) and we counted the cell
numbers under a microscope in five random fields ( × 200).
Cell counting kit-8 (CCK-8) assay
CCK-8 assay was performed as described previously [49].
Popliteal LN metastasis model
Female nude mice (4 weeks old) were purchased from the
Experimental Animal Center, Southern Medical University
(Guangzhou, PR China). The studies were approved by the
Institutional Animal Research Ethics Committee of South-
ern Medical University. Siha/anti-221-3p cells (5 × 106)
stably expressing mCherry were injected into the footpads
of the mice. Tumor size (mm3) was measured every 4 days
and calculated by the formula: volume= (width)2 × length/
2. The mice were killed when the primary tumors reached a
comparable size of ~ 150 mm3, then the popliteal LNs were
paraffin embedded and analyzed for mCherry expression by
IHC with anti-mCherry antibody (Abcam). Positive LNs
were identified by detecting mCherry staining under a
Nikon upright microscope. The ratio of metastasis-positive
to total dissected popliteal LN was calculated.
ELISA
VEGF-C in the culture supernatants of tumor cells was
quantified using a human VEGF-C ELISA Kit
(eBioscience) according to the manufacturer’s protocol.
Statistical analysis
SPSS V.13.0 software was used for statistical analysis. Data
are expressed as the mean ± standard deviation. One-way
analysis of variance was used for comparisons among
groups. The χ2-test was applied for categorical variables.
Correlation analysis was performed using the Spearman
rank test. Differences were considered to be statistically
significant when P < 0.05.
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